T1	intervention 0 28	Impact + resistance training
T2	eligibility 74 120	prematurely menopausal breast cancer survivors
T3	No-of-participants 818 820	71
T4	average-age 836 846	46.5 years
T5	control 1042 1058	exercise placebo
T6	duration 1078 1084	1 year
T7	outcome-Measure 1100 1117	hip and spine BMD
T8	outcome-Measure 1155 1171	body composition
T9	outcome-Measure 1200 1217	lean and fat mass
T10	outcome-Measure 1245 1266	bone turnover markers
T11	outcome-Measure 1320 1346	urinary deoxypryrodinoline
T12	outcome 1389 1447	no significant group Ã— time interactions for bone outcomes
T13	outcome 1570 1633	POWIR increased BMD at the hip and slowed BMD loss at the spine
T14	outcome 1837 1853	increases in %BF
T15	outcome 1948 1967	improvements in %BF
